Importance Novel sensitive methods for detection and monitoring of residual disease can
improve postoperative risk stratification with implications for patient selection for adjuvant …

PURPOSE Novel sensitive methods for early detection of relapse and for monitoring therapeutic
efficacy may have a huge impact on risk stratification, treatment, and ultimately outcome …

The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized
by large biological heterogeneity with variable clinical outcomes. Here, we perform an …

Overtreatment with cisplatin-based chemotherapy is a major issue in the management of
muscle-invasive bladder cancer (MIBC), and currently none of the reported biomarkers for …

Background At least half of the patients diagnosed with non–muscle-invasive bladder
cancer (NMIBC) experience recurrence and approximately 15% will develop progression to …

There have been reports of associations between cesarean section delivery and the risk of
childhood asthma, potentially mediated through changes in the gut microbiota. We followed …

… Author links open overlay panel Emil Christensen a , Karin Birkenkamp-Demtröder a , Iver
Nordentoft a , Søren Høyer b , Kirstin van der Keur c , Kim van Kessel c , Ellen Zwarthoff c , …

Histological and molecular analyses of urothelial carcinoma often reveal intratumoural and
intertumoural heterogeneity at the genomic, transcriptional and cellular levels. Despite the …

Detection of circulating tumor DNA (ctDNA) post‐treatment is an emerging marker of residual
disease. ctDNA constitutes only a minor fraction of the cell‐free DNA (cfDNA) circulating in …

Of the patients undergoing radical cystectomy, 20–80% experience relapse. Minimally
invasive methods for early detection of metastatic relapse after cystectomy and for monitoring …